

AVI BIOPHARMA INC  
Form DEFA14A  
May 24, 2010

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of  
the Securities Exchange Act of 1934 (Amendment No. )

Filed by the Registrant  X

Filed by a Party other than the Registrant  O

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to §240.14a-12

AVI BIOPHARMA, INC.  
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  - (1) Title of each class of securities to which transaction applies:
  - (2) Aggregate number of securities to which transaction applies:
  - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
  - (4) Proposed maximum aggregate value of transaction:
  - (5) Total fee paid:
- Fee paid previously with preliminary materials.
- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  - (1) Amount Previously Paid:
  - (2) Form, Schedule or Registration Statement No.:
  - (3) Filing Party:
  - (4) Date Filed:

The Proxy Statement of AVI BioPharma, Inc. ( AVI or the Company ) mailed to shareholders on or about May 4, 2010 contained cross-references on pages 25, 28, and 34 of the Proxy Statement to note 12 (Subsequent Events) to the financial statements filed with the Company s Amendment No. 1 to the Company s Annual Report on Form 10-K/A, which was filed with the Securities and Exchange Commission ( SEC ) on April 28, 2010. All such references should be deleted and replaced with cross-references to note 12 (Subsequent Events (unaudited)) to the financial statements filed with the Company s Amendment No. 2 to the Company s Annual Report on Form 10-K/A, which was filed with the SEC on May 24, 2010.

---